23.2 Necrotizing Soft Tissue Infections & Severe CNS Infections

ABFM Family Medicine Certification Study Guide Exam

Track your progress as you read

Finished sections get a check mark.

1 Chapter 1: Exam Structure, Blueprint & Clinical Decision-Making

1.1 Exam Blueprint, FMCLA vs. One-Day Exam & Board Scoring 1.2 Clinical Reasoning, Test-Taking Strategy & Ambiguity Management 1.3 Evidence-Based Medicine & Clinical Practice Guidelines in Primary Care

2 Chapter 2: Healthcare Systems, Practice Management & Quality

2.1 Practice Management, Billing, Coding & Documentation 2.2 Quality Improvement, Patient Safety & Diagnostic Stewardship 2.3 Interprofessional Team-Based Care & Care Coordination

3 Chapter 3: Ethics, Law, Biostatistics & Health Equity

3.1 Medical Ethics, Informed Consent & Surrogate Decision-Making 3.2 Biostatistics, Clinical Epidemiology & Diagnostic Test Interpretation 3.3 Social Determinants of Health, Health Equity & Cultural Humility 3.4 Physician Wellness, Burnout Prevention & Professionalism

4 Chapter 4: Lifestyle Counseling & Behavior Change

4.1 Alcohol Use Screening & Brief Intervention 4.2 Illicit Drug & Cannabis Counseling 4.3 Tobacco & Vaping Cessation Counseling

5 Chapter 5: Nutrition, Physical Activity & Chronic Disease Prevention

5.1 Dietary Counseling for Obesity & Chronic Disease Prevention 5.2 Exercise Prescription & Physical Activity Counseling 5.3 Genetic Risk Assessment & Family History Counseling

6 Chapter 6: Routine Adult Immunizations

6.1 ACIP Adult Respiratory Vaccines: Influenza, COVID-19, RSV & Pneumococcal 6.2 ACIP Adult Non-Respiratory Vaccines: Tdap, Shingrix, HPV & Hep B 6.3 Immunizations in Special Populations: Pregnancy, Asplenia & Immunocompromise

7 Chapter 7: Pediatric Health Maintenance & Surveillance

7.1 Newborn Examination & Early Postnatal Care 7.2 Well-Child Care, Developmental Surveillance & Milestones 7.3 Pediatric & Adolescent Screening: Vision, Hearing, Anemia & Lead 7.4 Pediatric Oral Health, Dental Screening & Fluoride

8 Chapter 8: Behavioral Health & Safety Screening

8.1 Primary Care Depression, Anxiety & Behavioral Health Screening 8.2 Domestic Violence, Intimate Partner Violence & Firearm Safety 8.3 Occupational Health & Recreational Safety Counseling

9 Chapter 9: Adult Preventive Screening: Cardiovascular & Metabolic

9.1 Cardiovascular Disease & Hypertension Screening 9.2 Type 2 Diabetes Screening & Prediabetes Risk Stratification 9.3 Abdominal Aortic Aneurysm & Osteoporosis Screening

10 Chapter 10: Adult Cancer Screening: Breast & Gynecologic

10.1 Breast Cancer Screening & Risk-Assessment 10.2 Cervical Cancer Screening & ASCCP Algorithms 10.3 Skin Cancer Clinical Assessment & Counseling

11 Chapter 11: Adult Cancer Screening: Colorectal, Lung & Prostate

11.1 Colorectal Cancer Screening Modalities & Intervals 11.2 Lung Cancer Screening with Low-Dose CT 11.3 Prostate Cancer Screening & Shared Decision-Making

12 Chapter 12: Sexual Health, Infectious Disease Screening & Contraception

12.1 Sexual Health Counseling & Risk-Reduction Strategies 12.2 STI Screening: Chlamydia, Gonorrhea, Syphilis & Trichomoniasis 12.3 Bloodborne Infectious Disease Screening: HIV & Hepatitis C

13 Chapter 13: Reproductive Life Planning, Lactation & Preoperative Care

13.1 Preconception Planning & Comprehensive Contraception Management 13.2 Lactation Support & Breastfeeding Counseling 13.3 Preoperative Medical Evaluation & Pre-Participation Sports Exam

14 Chapter 14: Emergent Cardiovascular Conditions

14.1 Acute Coronary Syndromes & Myocardial Infarction 14.2 Acute Chest Pain Risk Stratification & Triage 14.3 Acute or Critical Valvular Heart Emergencies

15 Chapter 15: Cardiac Arrhythmias, Heart Failure & Hypertensive Crises

15.1 Acute Atrial & Ventricular Arrhythmias 15.2 Acute Decompensated Heart Failure & Cardiogenic Shock 15.3 Hypertensive Emergency & Urgency Management

16 Chapter 16: Vascular & Thromboembolic Emergencies

16.1 Pulmonary Embolism & Deep Vein Thrombosis 16.2 Acute Aortic Syndromes & Peripheral Vascular Emergencies 16.3 Critical Limb Ischemia & Acute Arterial Occlusion

17 Chapter 17: Neurologic Emergencies: Stroke & Altered Consciousness

17.1 Acute Ischemic Stroke & Intracranial Hemorrhage 17.2 Syncope Evaluation & Status Epilepticus 17.3 Acute Delirium, Encephalopathy & Severe Confusion

18 Chapter 18: Neurologic Trauma & Acute Cranial Emergencies

18.1 Concussion, Moderate-to-Severe TBI & Intracranial Injury 18.2 Thunderclap & Acute Severe Secondary Headaches 18.3 Acute Ophthalmologic Emergencies

19 Chapter 19: Acute Abdominal, Pelvic & Gastrointestinal Emergencies

19.1 Acute Abdominal & Pelvic Pain Triage 19.2 Upper & Lower Gastrointestinal Bleeding 19.3 Acute Hepatic Failure, Cholangitis & Severe Jaundice

20 Chapter 20: Acute Pulmonary & Airway Emergencies

20.1 Acute Hypoxic Respiratory Failure & ARDS 20.2 Severe Community-Acquired Pneumonia & Empyema 20.3 Acute Severe Epistaxis & Airway Obstruction

21 Chapter 21: Acute Traumatic Injuries & Wound Care

21.1 Major Trauma Resuscitation & Initial Assessment 21.2 Burn Assessment, Inhalation Injury & Resuscitation 21.3 Laceration Management, Complex Wounds & Animal Bites

22 Chapter 22: Acute Orthopedic & Musculoskeletal Emergencies

22.1 Acute Ambulatory Fractures & Initial Splinting 22.2 Compartment Syndrome & Major Orthopedic Trauma 22.3 Septic Arthritis & Acute Microcrystalline Crises

23 Chapter 23: Severe Infections, Sepsis & Systemic Emergencies

23.1 Sepsis, Septic Shock & Initial Fluid Resuscitation 23.2 Necrotizing Soft Tissue Infections & Severe CNS Infections 23.3 Anaphylaxis Diagnosis, Epinephrine Dosing & Airway Protection

24 Chapter 24: Metabolic, Endocrine & Electrolyte Emergencies

24.1 Diabetic Ketoacidosis & Hyperosmolar Hyperglycemic State 24.2 Critical Electrolyte Emergencies: Dyskalemias & Dysnatremias 24.3 Severe Calcium Abnormalities & Acute Adrenal Crisis

25 Chapter 25: Hematologic, Urologic & Dental Emergencies

25.1 Severe Symptomatic Anemias & Coagulopathic Emergencies 25.2 Testicular Torsion, Priapism & Acute Urinary Retention 25.3 Urgent Odontogenic Infections & Dental Trauma

26 Chapter 26: Psychiatric, Behavioral & Obstetric/Gynecologic Emergencies

26.1 Suicidal Ideation, Acute Agitation & Behavioral Emergencies 26.2 Acute Physical & Sexual Assault Care 26.3 Life-Threatening Vaginal Bleeding & Ectopic Pregnancy 26.4 Environmental Heat Stroke & Severe Hypothermia

27 Chapter 27: Acute Head, Neck & Neurologic Symptoms

27.1 Primary Acute Headaches: Migraine, Tension & Cluster 27.2 Concussion & Minor Closed Head Injury Evaluation 27.3 Transient Ischemic Attack Evaluation & ABCD2 Risk Scoring

28 Chapter 28: Acute Cranial Nerves, Hearing & Sensory Symptoms

28.1 Peripheral Neuropathies: Bell's Palsy, Carpal Tunnel & Radiculopathy 28.2 Acute Tinnitus, Sudden Sensorineural Hearing Loss & Cerumen Impaction 28.3 Acute Dizziness, Benign Paroxysmal Positional Vertigo & Vestibular Neuritis

29 Chapter 29: Acute Upper Respiratory Tract Infections

29.1 Acute Viral Rhinosinusitis vs. Bacterial Rhinosinusitis 29.2 Acute Pharyngitis: Group A Streptococcus & Centor Criteria 29.3 Acute Otitis Media, Otitis Externa & Serous Effusion

30 Chapter 30: Acute Lower Respiratory Infections & Cough

30.1 Influenza, COVID-19 & Viral Respiratory Syndromes 30.2 Acute Bronchitis & Lower Respiratory Tract Infections 30.3 Ambulatory Community-Acquired Pneumonia

31 Chapter 31: Allergic, Nasal & Non-Infectious Pulmonary Conditions

31.1 Allergic Rhinitis & Acute Non-Anaphylactic Allergic Reactions 31.2 Acute Dyspnea in Ambulatory Care 31.3 Interstitial Lung Diseases & Sarcoidosis Presentation

32 Chapter 32: Acute Chest, Cardiac & Vascular Symptoms

32.1 Palpitations Evaluation & Arrhythmia Triage in Primary Care 32.2 Deep Vein Thrombosis & Superficial Thrombophlebitis 32.3 Ambulatory Hypotension & Orthostasis Evaluation

33 Chapter 33: Acute Upper Gastrointestinal Conditions

33.1 Peptic Ulcer Disease & Gastritis 33.2 Dysphagia, Esophagitis & Acute Esophageal Disorders 33.3 Acute Nausea, Vomiting & Foodborne Illness

34 Chapter 34: Acute Lower Gastrointestinal Conditions

34.1 Acute Infectious Diarrhea & Gastroenteritis 34.2 Acute Constipation & Functional Bowel Changes 34.3 Ano-Rectal Disorders: Hemorrhoids, Fissures, Abscesses & Pruritus Ani

35 Chapter 35: Inflammatory, Functional & Malabsorptive GI Disorders

35.1 Acute Flares of Inflammatory Bowel Disease 35.2 Irritable Bowel Syndrome: Diagnosis, Subtyping & Management 35.3 Celiac Disease & Malabsorption Syndromes

36 Chapter 36: Acute Abdominal, Hepatic & Biliary Disorders

36.1 Ambulatory Abdominal & Pelvic Pain Triage 36.2 Acute Cholecystitis, Biliary Colic & Pancreatitis 36.3 Acute Liver Injury & Viral Hepatitis

37 Chapter 37: Acute Abdominal Wall, Hernias & Dental Conditions

37.1 Abdominal Wall, Inguinal & Ventral Hernias 37.2 Acute Dental Pain, Odontogenic Abscess & Aphthous Ulcers 37.3 Acute Edema: Unilateral vs. Bilateral Diagnostic Evaluation

38 Chapter 38: Acute Infectious Dermatoses

38.1 Bacterial Skin Infections: Impetigo, Cellulitis & Cutaneous Abscesses 38.2 Fungal Skin Infections: Tinea Corporis, Cruris, Pedis & Onychomycosis 38.3 Viral Cutaneous Infections: Herpes Simplex, Zoster & Molluscum Contagiosum

39 Chapter 39: Inflammatory, Allergic & Autoimmune Dermatoses

39.1 Atopic Dermatitis, Contact Dermatitis & Eczematous Flares 39.2 Non-Infectious Rashes: Urticaria, Drug Eruptions & Erythema Multiforme 39.3 Cutaneous Malignancies & Premalignant Lesions: AK, BCC, SCC & Melanoma

40 Chapter 40: Acute Shoulder, Elbow & Upper Extremity Injuries

40.1 Rotator Cuff Pathology, Tendinopathy & Shoulder Impingement 40.2 Lateral & Medial Epicondylitis, Olecranon Bursitis & Elbow Sprains 40.3 Wrist & Hand Soft-Tissue Injuries: De Quervain, TFCC & Finger Sprains

41 Chapter 41: Acute Knee, Ankle & Lower Extremity Injuries

41.1 Meniscal Tears, Ligamentous Knee Injuries & Patellofemoral Pain 41.2 Ankle Sprains, Ottawa Ankle Rules & Achilles Tendinopathy 41.3 Plantar Fasciitis, Shin Splints & Overuse Syndromes

42 Chapter 42: Acute Ambulatory Fractures & Dislocations

42.1 Distal Radius, Scaphoid & Common Upper Extremity Fractures 42.2 Metatarsal, Clavicle & Common Lower Extremity Fractures 42.3 Joint Dislocation Management: Nursemaid's Elbow & Shoulder Subluxation

43 Chapter 43: Acute Axial Musculoskeletal Pain & Falls

43.1 Acute Low Back Pain: Red Flags, Strain & Disc Herniation 43.2 Acute Cervical Strain, Whiplash & Axial Neck Pain 43.3 Evaluation of Falls in Ambulatory & Older Patients

44 Chapter 44: Acute Inflammatory Arthropathies & Generalized Pain

44.1 Acute Inflammatory Arthritis & Spondyloarthropathies 44.2 Myalgias, Rhabdomyolysis & Post-Viral Pain Syndromes 44.3 Acute Non-Headache Pain Management Strategies

45 Chapter 45: Acute Renal, Urinary & Genitourinary Conditions

45.1 Uncomplicated UTI, Pyelonephritis & Acute Urethritis 45.2 Hematuria Workup & Glomerulonephritis 45.3 Nephrolithiasis & Acute Urinary Tract Obstruction

46 Chapter 46: Acute Male Genitourinary & Prostatic Conditions

46.1 Acute Prostatitis, Epididymitis & Orchitis 46.2 Acute Scrotal Pain: Torsion vs Appendage, BPH & Male Genital Emergencies 46.3 Acute Urinary Retention & Incontinence Evaluation

47 Chapter 47: Acute Women's Health & Early Pregnancy Care

47.1 Early Pregnancy Diagnosis, Dating & Initial Complications 47.2 Abnormal Uterine Bleeding & Acute Menstrual Disorders 47.3 Premenstrual Syndrome & Premenstrual Dysphoric Disorder

48 Chapter 48: Breast Disorders, STIs & Pediatric Elimination

48.1 Palpable Breast Mass, Mastitis & Nipple Discharge 48.2 Sexually Transmitted Infections: Diagnosis, Staging & CDC Guidelines 48.3 Pediatric Enuresis & Encopresis

49 Chapter 49: Systemic Signs, Metabolic Dysregulation & Miscellaneous Infections

49.1 Acute Fever, Sepsis Screening & FUO in Primary Care 49.2 Acute Hyperglycemia & Symptomatic Hypoglycemia 49.3 Electrolyte Abnormalities: Mild-to-Moderate Disturbances 49.4 Vector-Borne, Tick-Borne & Rickettsial Illnesses

50 Chapter 50: Chronic Cardiovascular Diseases: Hypertension & Ischemia

50.1 Essential Hypertension Management: 2025 AHA/ACC Guideline & JNC Strategies 50.2 Chronic Coronary Artery Disease & Post-MI Secondary Prevention 50.3 Chronic Heart Failure: HFrEF, HFpEF & Quadruple GDMT

51 Chapter 51: Chronic Vascular, Valvular & Dyslipidemic Diseases

51.1 Peripheral Arterial Disease & Claudication 51.2 Chronic Valvular Heart Disease & Murmur Evaluation 51.3 Lipid Disorders & ASCVD Risk-Based Statin Therapy

52 Chapter 52: Chronic Respiratory Diseases: Asthma & COPD

52.1 Chronic Asthma Management: GINA Stepwise SMART Therapy 52.2 Chronic Obstructive Pulmonary Disease: GOLD Recommendations 52.3 Solitary Pulmonary Nodule Evaluation & Fleischner Society Criteria

53 Chapter 53: Chronic Metabolic Diseases: Diabetes Mellitus

53.1 Type 2 Diabetes Management: ADA Pharmacotherapy Algorithms 53.2 Type 1 Diabetes: Basal-Bolus Insulin, CGMs & Diabetic Complications 53.3 Diabetic Microvascular & Macrovascular Disease Surveillance

54 Chapter 54: Obesity, Nutrition & Metabolic Bone Diseases

54.1 Medical & Behavioral Management of Obesity & Incretin Mimetics 54.2 Osteoporosis & Metabolic Bone Disease: DEXA, FRAX & Antiresorptives 54.3 Nutritional Deficiencies: Vitamin D, B12, Iron & Malnutrition

55 Chapter 55: Chronic Endocrine Disorders

55.1 Primary & Subclinical Hypothyroidism, Hyperthyroidism & Nodules 55.2 Adrenal Disorders: Addison's Disease & Cushing's Syndrome 55.3 Hypercalcemia, Hyperparathyroidism & Pituitary Disorders

56 Chapter 56: Chronic Kidney Disease & Venous Disorders

56.1 Chronic Kidney Disease: KDIGO Staging & Renoprotective Therapy 56.2 Chronic Venous Insufficiency, Stasis Dermatitis & Lymphedema 56.3 Chronic Electrolyte & Acid-Base Management in CKD

57 Chapter 57: Chronic Gastrointestinal & Hepatic Diseases

57.1 Gastroesophageal Reflux Disease, Barrett's Esophagus & Dyspepsia 57.2 Chronic Liver Disease: MASLD/NAFLD, Cirrhosis & Portal Hypertension 57.3 Viral Hepatitis B & C: Long-Term Monitoring & DAA Therapy

58 Chapter 58: Colorectal Surveillance & Chronic Pancreaticobiliary Care

58.1 Post-Polypectomy Colorectal Polyp Surveillance Guidelines 58.2 Chronic Pancreatitis & Exocrine Pancreatic Insufficiency 58.3 Chronic Nausea, Gastroparesis & Functional GI Disorders

59 Chapter 59: Chronic Musculoskeletal & Rheumatologic Disorders

59.1 Osteoarthritis: Hip, Knee & Hand Management 59.2 Spinal Conditions: Spinal Stenosis, Spondylolisthesis & Compression Fractures 59.3 Chronic Myopathies & Fibromyalgia Syndrome

60 Chapter 60: Chronic Neurologic & Neurodegenerative Disorders

60.1 Dementia: Alzheimer's, Vascular & Lewy Body Disease 60.2 Parkinson's Disease & Essential Tremor 60.3 Epilepsy: Chronic Antiseizure Medications & Post-Stroke Care

61 Chapter 61: Chronic Peripheral Nerves, Pain & Sensory Disorders

61.1 Diabetic & Chronic Peripheral Neuropathies 61.2 Chronic Pain Syndromes & Chronic Daily Headaches 61.3 Chronic Tinnitus, Presbycusis & Persistent Dizziness

62 Chapter 62: Chronic Psychiatric Disorders

62.1 Major Depressive Disorder & Generalized Anxiety Disorder 62.2 Bipolar Disorder: Maintenance Pharmacotherapy & Lithium Monitoring 62.3 Adult & Pediatric Attention-Deficit/Hyperactivity Disorder

63 Chapter 63: Chronic Behavioral Health & Neurodevelopmental Conditions

63.1 Chronic Behavioral Conditions: PTSD, OCD & Somatization 63.2 Autism Spectrum Disorder & Intellectual Disabilities 63.3 Eating Disorders: Anorexia Nervosa, Bulimia & Binge Eating

64 Chapter 64: Chronic Substance Use Disorders & Tobacco Cessation

64.1 Alcohol Use Disorder: Pharmacotherapy & Relapse Prevention 64.2 Opioid & Stimulant Use Disorders: MOUD & Harm Reduction 64.3 Longitudinal Tobacco Cessation Pharmacotherapy

65 Chapter 65: Chronic Dermatologic Conditions

65.1 Acne Vulgaris, Rosacea & Seborrheic Dermatitis 65.2 Chronic Plaque Psoriasis & Biologic Therapies 65.3 Chronic Eczema, Hidradenitis Suppurativa & Cutaneous Lupus

66 Chapter 66: Chronic Reproductive, Infectious & Geriatric Special Care

66.1 Chronic Menstrual Disorders, Infertility & Sexual Dysfunction 66.2 Menopause Management & Hormone Replacement Therapy 66.3 Chronic HIV Infection Management & Primary Care Integration 66.4 Gender-Affirming Primary Care & Hormone Therapy 66.5 Advance Care Planning, Palliative Care & End-of-Life Symptom Control

67 Chapter 67: Continuity Care: Sleep, Fatigue, Cancer, Pregnancy & the Adult Preventive Visit

67.1 Chronic Insomnia & Obstructive Sleep Apnea 67.2 Chronic Malaise, Fatigue & ME/CFS 67.3 Primary Care During Cancer Treatment & Survivorship 67.4 Routine Prenatal Care & Longitudinal Pregnancy Management 67.5 The Periodic Adult Health Examination & Medicare Annual Wellness Visit

23.2 Necrotizing Soft Tissue Infections & Severe CNS Infections

Key Takeaways Explain This Topic AI

Pain out of proportion to physical examination findings is the single most sensitive early clinical sign of a necrotizing soft tissue infection (NSTI); soft-tissue crepitus and cutaneous bullae are late manifestations heralding advanced liquefactive tissue necrosis.

A low or normal LRINEC score (<6) NEVER rules out necrotizing fasciitis when clinical suspicion is present; emergent surgical exploration with radical operative debridement is the definitive diagnostic and life-saving therapeutic procedure.

Empiric antimicrobial therapy for NSTI mandates triple coverage: Vancomycin (MRSA) plus Piperacillin-tazobactam or Meropenem (Gram-negative bacilli and anaerobes) plus Clindamycin (suppresses bacterial protein synthesis at the 50S ribosome, halting toxin production and overcoming the stationary-phase Eagle effect).

In acute bacterial meningitis, neuroimaging must never delay antimicrobial therapy; if head CT is indicated prior to lumbar puncture (altered consciousness, immunocompromise, focal deficit, new seizure, papilledema, or prior CNS disease), blood cultures must be drawn and empiric antibiotics plus dexamethasone administered immediately before CT.

Empiric meningitis therapy comprises IV Ceftriaxone plus IV Vancomycin, with the mandatory addition of IV Ampicillin for adults >=50 years or immunocompromised hosts to cover Listeria monocytogenes; IV Dexamethasone (10 mg) must be administered prior to or with the first antibiotic dose to reduce mortality and sensorineural hearing loss.

Last updated: September 2026

Necrotizing Soft Tissue Infections (NSTI / Necrotizing Fasciitis)

Necrotizing soft tissue infections (NSTIs) represent aggressive, rapidly destructive infections involving the skin, subcutaneous fat, and superficial and deep fascial planes. Without hyperacute surgical intervention and directed antimicrobial therapy, NSTIs carry a mortality rate exceeding 30% to 50% .

Microbiological Classification NSTI MICROBIOLOGICAL CLASSIFICATION

• ┌─────────────────────────────────┐ ┌─────────────────────────────────┐
• │ TYPE I: POLYMICROBIAL (70-80%)│ │ TYPE II: MONOMICROBIAL (15-20%)│
• ├─────────────────────────────────┤ ├─────────────────────────────────┤
• │ • Mixture: Anaerobes + Aerobes │ │ • Group A Streptococcus (GAS) │
• │ (Bacteroides, Clostridium, │ │ (Streptococcus pyogenes) │
• │ Peptostreptococcus PLUS │ │ • With/without S. aureus (MRSA) │
• │ E. coli, Klebsiella, Proteus)│ │ • Any age; healthy young hosts │
• │ • Elderly, Diabetics, PVD │ │ • Blunt trauma, lacerations, IVDU│
• │ • Fournier Gangrene (Perineum) │ │ • Severe Toxic Shock Syndrome │
• └─────────────────────────────────┘ └─────────────────────────────────┘

Type I (Polymicrobial) :

Represents 70% to 80% of all NSTI cases.

Microbiology : Synergistic mixture of obligate anaerobes ( Bacteroides fragilis , Clostridium perfringens , Peptostreptococcus ) and facultative Gram-negative aerobic bacilli ( Escherichia coli , Klebsiella pneumoniae , Proteus mirabilis ) or enterococci.

Host Risk Factors : Poorly controlled diabetes mellitus, peripheral vascular disease, chronic kidney disease, obesity, malnutrition, and postoperative or decubitus wound breakdown.

Fournier Gangrene : A specific Type I polymicrobial necrotizing fasciitis of the male or female perineum, scrotum, and perianal region. Often originates from an occult perirectal abscess, urethral stricture, or minor cutaneous abrasion. Spreads rapidly along Colles, Dartos, and Scarpa fascial planes.

Type II (Monomicrobial) :

Represents 15% to 20% of cases.

Microbiology : Group A Streptococcus ( Streptococcus pyogenes / GAS), either alone or co-infecting with Staphylococcus aureus (including community-acquired MRSA).

Host Risk Factors : Can occur in any age group, including previously healthy, immunocompetent children and young adults . Often precipitated by minor blunt non-penetrating trauma (muscle hematoma), insect bites, surgical incisions, childbirth, or intravenous drug use.

Virulence : GAS strains express virulent surface M-proteins and release pyrogenic exotoxins ( SPE-A, SPE-B, SPE-C ), frequently triggering concurrent Streptococcal Toxic Shock Syndrome (STSS) with profound capillary leak, multiorgan failure, and refractory shock.

Type III (Marine / Waterborne) :

Monomicrobial infection caused by Vibrio vulnificus or Aeromonas hydrophila . Associated with open wound exposure to warm seawater, brackish water, or handling raw marine oysters, especially in patients with chronic liver disease, hemochromatosis, or cirrhosis (iron overload markedly accelerates Vibrio proliferation).

Type IV (Fungal) :

Zygomycetes ( Mucor , Rhizopus , Lichtheimia ) or Candida species, occurring predominantly in immunocompromised, neutropenic, or severe burn patients.

Pathophysiological Progression

Bacteria enter subcutaneous planes, producing bacterial enzymes (hyaluronidase, collagenase, heparinase, streptokinase) that rapidly hydrolyze fascial matrices. Infection spreads horizontally along the relatively hypovascular deep fascia at rates exceeding 1 inch per hour without initially involving the overlying muscular layers or epidermis. As fascial inflammation surges:

Endothelial destruction triggers diffuse microvascular thrombosis of the nutrient perforating cutaneous arterioles that traverse the deep fascia to supply the overlying skin.

Overlying skin and subcutaneous tissues undergo acute ischemia, evolving into liquefactive necrosis ("dishwater pus").

Cutaneous nerve branches are destroyed, producing localized dermal anesthesia .

Clinical Manifestations: Early vs. Late Signs

The Earliest & Most Sensitive Hallmark : Pain out of proportion to physical examination findings . The patient complains of excruciating, unbearable pain, yet physical examination may initially reveal only mild, ill-defined erythema and soft tissue swelling without obvious skin breakdown.

Pain extending significantly beyond the visible borders of cutaneous erythema .

Centrifugal Progression : The erythematous and indurated border visibly expands over a matter of hours. Marking the erythema border with a surgical pen reveals rapid migration outside the lines.

Late Signs (Diagnostic of Advanced Tissue Death) :

• Transition of skin color from bright red to dusky, bronze, violaceous, or gray-black patchiness;
• Tense bullae containing hemorrhagic, serosanguinous, or foul-smelling fluid;

Cutaneous anesthesia : The previously excruciatingly painful area becomes completely numb to pinprick due to thrombotic necrosis of cutaneous nerves;

Soft-tissue crepitus : Palpable crackling beneath the skin caused by gas production from anaerobic bacterial fermentation. Critical Board Pearl : Crepitus is a prominent sign in Type I polymicrobial / clostridial infections , but is completely absent in pure Type II monomicrobial Streptococcus pyogenes infections (GAS does not produce gas!);

Systemic septic shock, tachypnea, high fever or hypothermia, delirium, and multiorgan failure.

The LRINEC Score: Clinical Value and Critical Board Pitfall

The Laboratory Risk Indicator for Necrotizing Fasciitis (LRINEC) score was developed to help differentiate severe cellulitis from necrotizing fasciitis based on six routine laboratory parameters:

• Laboratory Parameter Value LRINEC Points
• C-Reactive Protein (CRP) <150 mg/L; ≥150 mg/L 0; 4
• Total White Blood Cell Count (WBC) <15 × 10³/µL; 15 – 25 × 10³/µL; >25 × 10³/µL 0; 1 ; 2
• Hemoglobin (Hb) >13.5 g/dL; 11.0 – 13.5 g/dL; <11.0 g/dL 0; 1 ; 2
• Serum Sodium (Na) ≥135 mEq/L; <135 mEq/L 0; 2
• Serum Creatinine ≤1.6 mg/dL (141 µmol/L); >1.6 mg/dL 0; 2
• Serum Glucose ≤180 mg/dL (10 mmol/L); >180 mg/dL 0; 1
• Scoring Interpretation & The Fatal Pitfall

Score ≤5 : Low risk (<50% probability).

Score 6 to 7 : Intermediate risk (suspicious for NSTI).

Score ≥8 : High risk (>75% strongly predictive probability of NSTI).

THE CRITICAL BOARD PEARL : While a high LRINEC score (≥6 to 8) strongly raises suspicion for necrotizing fasciitis, a low or normal LRINEC score (<6) NEVER excludes NSTI ! Meta-analyses indicate that the clinical sensitivity of the LRINEC score is only 68% to 80% . Approximately one out of every five patients with surgically confirmed necrotizing fasciitis presents with a LRINEC score <6 (particularly young patients, early presenters, and immunocompromised hosts). Waiting for laboratory tests or imaging studies when clinical signs suggest NSTI represents catastrophic malpractice.

Emergency Management of Necrotizing Soft Tissue Infections EMERGENCY NSTI MANAGEMENT

• ┌─────────────────────────────────────────────────────────────┐
• │ STEP 1: IMMEDIATE SURGICAL CONSULTATION FOR OR EXPLORATION │
• │ • Surgery is the ONLY definitive diagnostic & therapeutic │
• │ intervention; do NOT delay for imaging or labs! │
• │ • Bedside "Finger Test" if operating room is delayed │
• ├─────────────────────────────────────────────────────────────┤
• │ STEP 2: EMPIRIC TRIPLE INTRAVENOUS ANTIMICROBIAL REGIMEN │
• │ • VANCOMYCIN 15-20 mg/kg IV q8-12h (covers MRSA) PLUS │
• │ • PIPERACILLIN-TAZOBACTAM 3.375-4.5g IV q6h OR MEROPENEM 1g │
• │ (covers Gram-negative bacilli and anaerobes) PLUS │
• │ • CLINDAMYCIN 600-900 mg IV q8h │
• │ (shuts down 50S ribosomal toxin synthesis; Eagle effect) │
• ├─────────────────────────────────────────────────────────────┤
• │ STEP 3: AGGRESSIVE ICU RESUSCITATION & REPEAT OR DEBRIDEMENT│
• │ • 30 mL/kg balanced crystalloids + vasopressors │
• │ • Mandatory planned second-look OR debridement in 24-48 hrs │
• └─────────────────────────────────────────────────────────────┘
• 1. Emergent Operative Debridement

Surgical intervention is the single definitive therapy for necrotizing fasciitis. A delay to operative debridement exceeding 6 to 12 hours results in an exponential increase in mortality.

Operative Findings : Incision reveals grayish, necrotic deep fascia, absence of normal bleeding along fascial planes, lack of resistance to blunt finger dissection, and thin, foul-smelling exudate ("dishwater pus"). Radical debridement of all non-viable skin, subcutaneous fat, and fascia must be carried out to healthy, bleeding tissue.

The Bedside "Finger Test" : In an equivocal case where surgical access is delayed, infiltrate local lidocaine, make a 2-cm incision down to the deep fascia, and gently probe with an index finger. If the subcutaneous tissue separates effortlessly from the deep fascia with minimal resistance and no bleeding, the diagnosis of necrotizing fasciitis is confirmed.

2. The Empiric Triple Antimicrobial Regimen

Empiric antimicrobial coverage must immediately be initiated while the operating room is mobilized:

Vancomycin (15 to 20 mg/kg IV every 8 to 12 hours) to cover methicillin-resistant Staphylococcus aureus (MRSA);

Piperacillin-tazobactam (3.375 g to 4.5 g IV every 6 hours) OR Meropenem (1 g IV every 8 hours) to provide comprehensive coverage against Gram-negative enteric bacilli and anaerobes;

Clindamycin (600 mg to 900 mg IV every 8 hours).

Clindamycin Pharmacology & The Eagle Effect

Why is clindamycin mandatory when broad-spectrum beta-lactams are already administered?

50S Ribosomal Toxin Suppression : Clindamycin is a lincosamide antibiotic that binds specifically to the 50S ribosomal subunit , halting bacterial protein translation. By blocking protein synthesis, clindamycin immediately shuts down the synthesis and secretion of lethal bacterial exotoxins, including toxic shock syndrome toxin-1 (TSST-1) , streptococcal pyrogenic exotoxins ( SPE-A, SPE-B, SPE-C ), and antiphagocytic M-protein .

The "Eagle Effect" (Inoculum Effect) :

In severe, deep necrotizing infections with high bacterial densities, bacteria rapidly enter a stationary growth phase.

Beta-lactam antibiotics (penicillins, cephalosporins, carbapenems) require active cell wall synthesis and high expression of penicillin-binding proteins (PBPs) to exert their bactericidal activity. In high-inoculum stationary-phase infections, PBPs are dramatically downregulated, causing beta-lactams to lose their bactericidal efficacy (the Eagle effect).

Clindamycin acts independently of bacterial growth phase and cell wall synthesis , maintaining potent ribosomal suppression and clinical efficacy even in dense, stationary-phase inocula.

Severe Central Nervous System Infections: Acute Bacterial Meningitis

Acute bacterial meningitis is an emergent infection of the subarachnoid space associated with significant morbidity, permanent neurological sequelae, and mortality rates of 15% to 25% in adults.

Common Microbial Pathogens Across Demographics

Streptococcus pneumoniae (Pneumococcus) : The most frequent cause of bacterial meningitis in adults of all ages (~50% to 60%). Characterized by high mortality (~20%) and severe neurological sequelae (sensorineural hearing loss in up to 30%). Associated with concurrent pneumonia, acute otitis media, mastoiditis, sinusitis, asplenia, or basilar skull fractures with CSF leak.

Neisseria meningitidis (Meningococcus) : Common in adolescents, young adults, college dormitories, and military barracks. Also elevated in patients with terminal complement deficiencies (C5-C9) or those treated with eculizumab. Hallmark feature is a rapid petechial or purpuric rash on the trunk and extremities, which can progress to purpura fulminans, bilateral adrenal hemorrhage, and cardiovascular collapse ( Waterhouse-Friderichsen syndrome ).

Listeria monocytogenes : A motile, facultative intracellular Gram-positive rod. Accounts for up to 20% of meningitis in adults ≥50 years of age, pregnant women, alcoholics, and immunocompromised hosts (e.g., solid organ transplant, hematologic malignancy, corticosteroid therapy). Transmitted via ingestion of contaminated unpasteurized milk, soft cheeses, and processed deli meats. Critical Board Pearl : Listeria is intrinsically resistant to all cephalosporins!

Clinical Presentation

The Classic Triad : Fever, altered mental status, and neck stiffness (nuchal rigidity) . Board Fact : The complete triad is present in only approximately 44% of adult patients. However, >95% of patients present with at least two of the following four signs : headache, fever, neck stiffness, and altered mental status.

Meningeal Signs :

Nuchal Rigidity : Inability to flex the neck forward passively to touch the chin to the sternum due to reflex paraspinal muscle spasm.

Kernig Sign : Resistance or pain when extending the knee with the hip flexed at 90 degrees.

Brudzinski Sign : Involuntary flexion of the hips and knees elicited by passive flexion of the patient's neck.

Diagnostic Reality : Meningeal signs have high specificity (~95%) but low sensitivity (~50%); their absence never excludes meningitis.

Diagnostic Sequence: The Head CT Controversy

Lumbar puncture (LP) is the essential diagnostic test to confirm bacterial meningitis. However, performing an LP in the presence of an unrecognized mass lesion or elevated intracranial pressure can theoretically precipitate fatal transtentorial or tonsillar brain herniation . MENINGITIS DIAGNOSTIC & THERAPEUTIC SEQUENCE

• Patient Presents with Suspected Acute Bacterial Meningitis
• │
• ▼
• OBTAIN BLOOD CULTURES STAT (x2)
• │
• ▼

Does the patient meet ANY criteria for Head CT before LP?

• 1. Immunocompromised state (HIV, chemo, transplant)
• 2. History of CNS disease (stroke, mass, focal infection)
• 3. New-onset seizure within 1 week
• 4. Papilledema on funduscopy
• 5. Abnormal level of consciousness (GCS <15)
• 6. Focal neurologic deficit (cranial palsy, motor drift)
• │
• ┌───────────────┴───────────────┐
• │ YES │ NO
• ▼ ▼
• 1. ADMINISTER EMPIRIC ANTIBIOTICS PERFORM LUMBAR PUNCTURE
• PLUS DEXAMETHASONE IMMEDIATELY! IMMEDIATELY
• 2. Transport for Head CT │
• 3. If CT normal: Lumbar Puncture ▼
• │ ADMINISTER EMPIRIC ANTIBIOTICS
• │ PLUS DEXAMETHASONE STAT
• └───────────────┬───────┘
• ▼
• CSF ANALYSIS & TARGETED THERAPY
• The 6 Evidence-Based Indications for Head CT Prior to LP

According to the Infectious Diseases Society of America (IDSA) guidelines, a screening non-contrast Head CT is indicated prior to LP only if one or more of the following 6 criteria are present :

Immunocompromised state (known HIV/AIDS, active chemotherapy, post-organ transplant, high-dose corticosteroids);

History of central nervous system (CNS) disease (prior stroke, brain tumor, intracerebral hemorrhage, focal brain abscess);

• New-onset seizure within 1 week of presentation;
• Papilledema on funduscopic examination (loss of venous pulsations alone is insufficient);
• Abnormal level of consciousness (Glasgow Coma Scale <15, lethargy, stupor, or coma);

Focal neurologic deficit (e.g., asymmetric cranial nerve palsy, hemiparesis, asymmetric motor drift, aphasia).

THE CRITICAL CLINICAL RULE

If a patient meets criteria for a screening Head CT prior to LP:

BLOOD CULTURES MUST BE DRAWN IMMEDIATELY , and

EMPIRIC INTRAVENOUS ANTIMICROBIALS PLUS DEXAMETHASONE MUST BE ADMINISTERED BEFORE SENDING THE PATIENT TO THE CT SCANNER!

Never withhold or delay antibiotic administration to wait for neuroimaging. Each hour of delay in antibiotic administration significantly increases hospital mortality and permanent brain damage. CSF opening pressure, protein, glucose, and cell counts remain diagnostic for several hours after antibiotic administration, and CSF bacterial PCR and antigen testing remain positive even after bacterial cultures become sterilized.

Cerebrospinal Fluid (CSF) Analysis & Interpretation

CSF Parameter Normal Acute Bacterial Meningitis Viral (Aseptic) Meningitis Fungal / Cryptococcal Meningitis Tuberculous Meningitis

Opening Pressure 70 – 180 mm H2O Markedly Elevated (>200 – 350 mm H2O) Normal to Mildly Elevated (<200) Elevated (>200) Markedly Elevated (>250 – 400)

Appearance Crystal clear Turbid, purulent, cloudy Clear Clear to slightly cloudy Clear or "cobweb / pellicle" clot

WBC Count (cells/µL) <5 1,000 – 5,000+ (rarely <100) 50 – 500 100 – 500 100 – 500

WBC Differential >95% Lymphocytes >80% Neutrophils (PMNs) >50% Lymphocytes (early PMNs) >80% Lymphocytes >80% Lymphocytes

Protein (mg/dL) 15 – 45 Markedly Elevated (>100 – 500+) Mildly Elevated (50 – 100) Elevated (100 – 500) Markedly Elevated (>100 – 500+)

Glucose (mg/dL) 45 – 80 Severely Decreased (<40) Normal (>45) Decreased (<40) Severely Decreased (<30 – 40)

CSF:Serum Glucose Ratio ≥0.6 Markedly Decreased (<0.4) Normal (≥0.6) Decreased (<0.4) Markedly Decreased (<0.3)

Microbiology Negative Positive Gram stain (60-80%) Negative Gram stain / PCR positive Positive India Ink / Cryptococcal Ag Positive Acid-Fast Bacilli / PCR

• Empiric Antimicrobial Regimens & Corticosteroid Protocol
• 1. Age-Based Empiric Antimicrobial Regimens

Adults Aged 18 to 49 Years :

Ceftriaxone 2 g IV every 12 hours (or Cefotaxime 2 g IV every 4 to 6 hours) PLUS

Vancomycin 15 to 20 mg/kg IV every 8 to 12 hours (target trough 15 to 20 mcg/mL).

Rationale : Ceftriaxone provides bactericidal coverage against N. meningitidis and susceptible S. pneumoniae . Vancomycin is added to cover cephalosporin-resistant S. pneumoniae .

Adults Aged ≥50 Years OR Immunocompromised Hosts :

• Ceftriaxone 2 g IV every 12 hours PLUS
• Vancomycin 15 to 20 mg/kg IV every 8 to 12 hours PLUS

Ampicillin 2 g IV every 4 hours .

Rationale : Ampicillin is mandatory to cover Listeria monocytogenes , which possesses low-affinity penicillin-binding proteins that render it inherently resistant to third-generation cephalosporins.

Severe Beta-Lactam / Cephalosporin Anaphylaxis :

Vancomycin 15-20 mg/kg IV q8-12h PLUS Moxifloxacin 400 mg IV q24h PLUS Trimethoprim-sulfamethoxazole (TMP-SMX) 5 mg/kg IV q8h (to cover Listeria ).

2. Adjunctive Corticosteroid Protocol: Dexamethasone

Dose & Regimen : IV Dexamethasone 10 mg (or 0.15 mg/kg) administered prior to or concurrently with the first dose of antimicrobials , continued at 10 mg IV every 6 hours for 4 days.

Mechanism : Antimicrobial-induced bacterial lysis releases cell wall components (peptidoglycan, teichoic acid, endotoxin) into the subarachnoid space, triggering an intense burst of inflammatory cytokines (TNF-alpha, IL-1). Dexamethasone attenuates this inflammatory burst, reducing cerebral edema, intracranial pressure, and neuronal damage.

Clinical Benefit : The landmark European Dexamethasone Trial demonstrated that early dexamethasone significantly reduced mortality and prevented permanent sensorineural hearing loss in adults with Streptococcus pneumoniae meningitis .

Timing Rule : Corticosteroids must be administered before or with the first antibiotic dose . If antibiotics have already been administered, starting dexamethasone hours later provides no survival benefit. If CSF analysis or culture confirms an organism other than S. pneumoniae , dexamethasone should be discontinued (though IDSA guidelines permit continuation if Haemophilus influenzae is identified).

3. Post-Exposure Chemoprophylaxis for Close Contacts

Chemoprophylaxis is indicated for close contacts of patients with confirmed or suspected Neisseria meningitidis (household members, dorm roommates, day-care contacts, or healthcare providers exposed to respiratory secretions during endotracheal intubation):

Rifampin : 600 mg PO twice daily for 2 days (4 total doses); OR

Ciprofloxacin : 500 mg PO as a single dose (first-line in adults, unless fluoroquinolone resistance is documented); OR

Ceftriaxone : 250 mg IM as a single dose (preferred agent in pregnant women).

Loading diagram... Acute Bacterial Meningitis Diagnostic and Management Algorithm